Trial | NCT03628079  Report issue

Title

A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.
A Phase 2a TDM-guided Clinical Study on the Safety and Efficacy of Mebendazole in Patients With Advanced Gastrointestinal Cancer or Cancer of Unknown Origin

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    11
This study will evaluate the safety and efficacy of mebendazole (ReposMBZ) in patient with advanced gastrointestinal cancer or cancer of unknown origin. All patients will be given ReposMBZ for 16 weeks continuous treatment, individually dosed based on the serum concentration of mebendazole.
Mebendazole has been used extensively during long time for local gut helminthic infections at low dose but also at considerably higher doses during months to years against invasive echinococcus infections. Recent research has now clearly indicated that mebendazole has anticancer effect. Given these observations and the experience of excellent tolerance to mebendazole the current clinical trial protocol is based on the repositioning strategy to more extensively investigate whether mebendazole could be developed into a useful anticancer drug.
Study Started
May 25
2018
Primary Completion
Jan 16
2019
Study Completion
Jan 16
2019
Last Update
Jan 22
2020

Drug ReposMBZ

Capsules 50mg, 100mg, 200mg

  • Other names: Mebendazole

Single arm study Experimental

ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose. Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole.

Criteria 

Inclusion Criteria:

At least 18 years of age.
Histologically confirmed diagnosis of squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin.
Measurable disease according to RECIST 1.1.
Defined time to tumour progression on the standard/experimental treatment preceding the trial treatment.
Locally advanced or metastatic disease not amenable to standard treatment, i.e. progress on standard therapy or observed/expected intolerance to standard therapy.
- (removed via Amendment 1)
Pharmacological treatment attempt considered reasonable.

Females of childbearing potential should use adequate contraception throughout the study;

Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal)
Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable)
Intrauterine device (IUD)
Intrauterine hormone-releasing system (IUS)
Bilateral tubal occlusion
Vasectomized partner
Sexual abstinence
Signed informed consent.

Exclusion Criteria:

Anti-tumour therapy within 3 weeks prior to study drug administration day
Ongoing infection or other major recent or ongoing disease that, according to the investigator, poses an unacceptable risk to the patient.
WHO performance status ≥ 2.
Child-Pugh B or C liver function status if hepatocellular carcinoma.

Inadequate laboratory parameters reflecting major organ function i.e.:

neutrophils ≤ 1,3 x 109/l
platelets ≤ 100 x 109/l
bilirubin > 1.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALAT) > 5 x ULN
Glomerular filtration rate (GFR) <50 ml/min (calculated from P-creatinine)
Prothrombin complex/INR outside normal range
Current active participation in any other interventional clinical study.
Contraindications to the investigational product, e.g. known or suspected hypersensitivity or inability to oral drug administration.
Pregnancy or lactation.
Lack of suitability for participation in the study, e g expected difficulties to follow the protocol procedures, as judged by the Investigator.
No Results Posted